Back

Featured Topics

Behind The Science
Breast Cancer
Cancer Immunotherapy
Hematology
Lung Cancer
Manufacturing
Multiple Sclerosis
Oncology
Ophthalmology
Partnering
Respiratory Health
Rheumatology
About Us Contact Us Leadership Awards & Recognition Investors Suppliers Compliance
  • Twitter
  • Facebook
  • LinkedIn

Understanding Disease Diversity


Read More Stories
Nov 14, 2014

Benjamin Kramer*, M.D.

Vice President, Immunology and Ophthalmology Unit, Genentech

*While Benjamin was an employee at the time this article was published, he has since left Genentech.


At Genentech, our multi-disciplinary, multi-functional approach to drug development has one common thread: patients. Hanging on the buildings throughout our South San Francisco campus are banners of our patients’ faces. These serve to revitalize our daily goal of using the best science we can to make a difference in people’s lives. That commitment to science and patients has been the catalyst for discoveries across numerous diseases states, including rheumatoid arthritis (RA).

We have come to understand that, like many diseases, RA is heterogeneous. This means that there are different biologic pathways than can cause RA. That heterogeneity also means that people can get different types of RA that affect them in different ways. This insight led to the understanding that there needs to be more than one treatment modality for RA medications.

Heterogeneity also informs our larger approach to research; we use biomarkers, distinct genetic, or molecular characteristics that are indicators of a particular biological condition or process, to target particular pathways unique to a subset of patients. In asthma, for example, we were able to identify a biomarker in patients with a specific biological pathway for their asthma. We were then able to develop a compound to target that specific pathway. In our quest to find a biomarker in RA, our goal is to eventually reach a point where patients will be able to find an effective treatment without cycling through numerous medications.

Our industry is full of challenges and we make difficult decisions every day. What gives me hope as we continue to push the envelope from discovery through approval and beyond, is, that we continually ask ourselves, “What is the right decision for our patients?”


Tags:

  • Rheumatology

Read More Stories

Read about breakthrough science, the everyday people who make it happen, and the patients we serve.

  • Now Hiring
  • Find A Job
  • Professional Areas
  • Diversity & Inclusion
  • Chief Diversity Officer
  • Fostering Belonging
  • Health Equity
  • Advancing Inclusive Research
  • Transforming Society
  • Our 2021 Diversity & Inclusion Report
  • Our Work in Action
  • Kindergarten to Careers
  • For Scientists
  • Our Scientists
  • Publications
  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
  • For Patients
  • Our Medicines
  • Financial Support
  • Genentech Patient Foundation
  • Understanding Insurance
  • Medicine Information Support
  • Clinical Trial Information
  • Advancing Inclusive Research
  • Our Approach to Pricing
  • Patient Advocacy
  • Create With Us
  • Disease Education
  • For Medical Professionals
  • Our Medicines & Products
  • Our Pipeline
  • Medical Resources
  • Clinical Trial Information
  • Sunshine Act Compliance
  • Product Security
  • For Partners
  • Our Approach
  • What We Are Looking For
  • Partner With Us
  • Our Stories
  • For Media
  • News Features
  • Press Releases
  • Statements
  • Company Information
  • Sign Up For News Alerts
  • For Good
  • Giving
  • Diversity & Inclusion
  • Sustainability
  • About Us
  • Leadership
  • Policy & Advocacy
  • Our Focus on Oncology
  • Awards & Recognition
  • Investors
  • Suppliers
  • Our Approach to Pricing
  • CA Transparency in Supply
  • Compliance Overview
  • Contact Us
  • Call Us
  • Email Us
  • Visit us
  • Submit a Medical Inquiry
  • Submit a Media Inquiry
  • —
  • Privacy Policy
  • Terms & Conditions
  • Accessibility
© 2023 Genentech, Inc. All rights reserved. This site is intended for US residents only.